Browse

This podcast episode explores the critical role community oncology plays in the U.S. healthcare system and why supporting its growth and autonomy matters for patients and providers.

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with drugmakers.

A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.